Walbert Capital Management

Walbert Capital Management

Timothy Walbert established Walbert Capital Management in 2011, concurrent with his chairmanship of Horizon Therapeutics. The firm embodies a founder-operator's investment posture, channeling Walbert's own capital into biopharma ventures where his decades of operational and strategic experience can apply direct pressure. The firm deploys capital exclusively in life sciences and healthcare services, spanning seed-stage diagnostics through to pre-commercial biotech companies. Walbert's thesis is stage-agnostic, favoring platforms where his board-level intervention can influence clinical strategy, regulatory pathway, and commercial positioning. Confirmed portfolio activity includes early involvement with Eton Pharmaceuticals and Iterum Therapeutics. The investment framework merges personal capital with active board roles. Walbert does not operate a fund-of-funds structure; positions are direct equity stakes and board seats. Deployment is geographically concentrated in US-based biotech hubs, reflecting Walbert's Chicago and broader Midwest network built during Horizon's growth era. Co-investors have historically included venture syndicates and crossover funds aligned on specific therapeutic areas. Walbert's significant personal liquidity event — the 2023 acquisition of Horizon by Amgen for $27.8 billion — provides the capital base underpinning the firm's current and future deployment capacity. Walbert Capital Management is deliberately lean, operating without a public-facing multi-person investment team. In May 2023, Amgen completed its acquisition of Horizon Therapeutics, a transaction that both closed Walbert's defining operational chapter and recapitalized his personal investment capacity (per the firm's public record). The firm does not report headcount or AUM figures. No satellite offices or adjacent philanthropic vehicles are publicly disclosed, though Walbert's individual giving has historically tracked disease-state interests aligned with his investment activity. Walbert Capital Management's structural distinction lies in its identity as the post-exit vehicle of a single major operator, not a traditional family office or an arms-length asset manager. Unlike institutional venture firms, the firm's capital is the founder's alone; unlike most single family offices, its mandate concentrates entirely within the founder's personal area of operational expertise — biotech. This creates an unusually tight overlap between investment selection and the principal's ability to serve as an active, informed board member in every position.